4SC AG, the drug discovery and development company based in Martinsried, Germany, has announced the appointment of Bernd Hentsch as its new chief development officer, effective 1 July 2008.
Dr Hentsch held, until recently, the same position at TopoTarget, a biopharmaceutical company focused on cancer research. He replaces Gerhard Keilhauer, who has resigned from the management board for personal reasons. Dr Keilhauer had been a member of the board since 2001 and was primarily responsible for the implementation of all advanced pre-clinical and clinical studies at the company.
Source:
4SC press release, 6 June 2008.
Copyright Evernow Publishing 2008